# Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

> **NCT02842086** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 5399 (actual)

## Conditions studied

- Pre-Exposure Prophylaxis of HIV-1 Infection

## Interventions

- **DRUG:** F/TAF
- **DRUG:** F/TDF
- **DRUG:** F/TAF Placebo
- **DRUG:** F/TDF Placebo

## Key facts

- **NCT ID:** NCT02842086
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-02
- **Primary completion:** 2019-01-31
- **Final completion:** 2026-07
- **Target enrollment:** 5399 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842086, "Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT02842086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*